Cooperative Agreement U01DA066075
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $3M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Cambridge, MA 02138, USA
Similar Awards
- The National Institute on Drug Abuse awarded Wake Forest University Health Sciences $100,228 on November 7, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research investigating the role of synaptogyrin-3 in methamphetamine self-administration and dopamine dysfunction. The project examines synaptogyrin-3, a synaptic vesicle protein hypothesized to regulate dopamine release and uptake in the brain's reward circuitry. The research tests whether viral...
- The National Institute on Drug Abuse (NIDA), National Institutes of Health awarded The University of Texas Southwestern Medical Center a $2.792 million cooperative agreement on August 1, 2026, to conduct a randomized controlled trial of tirzepatide for methamphetamine use disorder under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds evaluation of the tolerability, safety, and preliminary efficacy of tirzepatide, a novel glucagon-like peptide 1 receptor agonist that...
- The National Institute on Drug Abuse awarded Virogenomics Biodevelopment, Inc. $399,889 on June 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to evaluate DRHQ, a novel CD74-targeting immunotherapeutic compound, for treatment of methamphetamine-induced central nervous system damage. The award funds preclinical research and development activities across two aims. In Aim 1, the recipient will evaluate whether DRHQ reduces infarct volume and improves cognitive function in...
- The National Institute on Drug Abuse awarded Cessation Therapeutics, Inc. a Cooperative Agreement of $7.315 million on September 15, 2025, to advance clinical development of CSX-1004, a human IgG1 monoclonal antibody designed to provide prophylaxis against fentanyl and fentanyl analog overdose. The award funds Phase 2 proof-of-concept fentanyl challenge studies in healthy subjects and subjects with opioid use disorder, with the ultimate target product profile being a fixed-dose subcutaneous...
- The National Institute on Drug Abuse awarded Oklahoma Medical Research Foundation $648,389 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate cell type-specific neurotensin signaling in methamphetamine use disorder. The research combines intravenous methamphetamine self-administration in genetically-modified mice, brain slice electrophysiology, and virus-induced expression of designer ligand-sensitive proteins to determine how neurotensin...
- The National Institute on Drug Abuse awarded Astrocyte Pharmaceuticals Inc. $399,680 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical efficacy studies of AST-004 as a treatment for psychostimulant use disorder. AST-004 is a small-molecule compound that acts on astrocytic receptors and enhances astrocyte mitochondrial function and ATP synthesis. The recipient will establish the compound's potential to reduce cocaine and methamphetamine...
- The National Institute on Drug Abuse awarded The University of Kentucky Research Foundation $2.175 million on September 30, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct a randomized controlled clinical trial evaluating non-abstinence treatment outcomes for methamphetamine use disorder. The trial will enroll 200 treatment-seeking individuals with methamphetamine use disorder and randomly assign them to two groups: one receiving financial incentives...
- The National Institute on Drug Abuse awarded Marshall University Research Corporation $147,500 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct preclinical evaluation of a naloxone-dexmedetomidine combination for treating methamphetamine-induced agitation in polysubstance intoxication. The research will test the repurposed drug combination in animal models to assess safety and efficacy as an alternative to benzodiazepine sedatives, which carry...
- The National Institute on Drug Abuse awarded the University of Oklahoma Health Sciences Center $116,664 on January 6, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support basic research examining neurotensin's effects on ventral tegmental area neuron physiology and methamphetamine use disorder. The research uses patch clamp electrophysiology and behavioral assessment techniques to investigate how neurotensin modulates reward behavior through its receptors NTR1 and...
- The National Institute on Drug Abuse, a component of the Department of Health and Human Services, awarded $2.46 million to The Regents of The University of California, San Francisco on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to conduct the first placebo-controlled trial of psilocybin therapy for methamphetamine use disorder, with focus on people living with HIV. The award funds a double-blind, randomized pilot study enrolling 30 participants with...